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NeutrophilsIn the PLATO study, ticagrelor was associated with fewer pulmonary infections and subsequent deaths than
clopidogrel. Neutrophils are a ﬁrst-line defence against bacterial lung infection; ticagrelor inhibits cellular uptake
of adenosine, a known regulator of neutrophil chemotaxis and phagocytosis.We assessedwhether the inhibition
of adenosine uptake by ticagrelor inﬂuences neutrophil chemotaxis and phagocytosis. Neutrophils and
erythrocytes were isolated from healthy volunteers. Concentration-dependent effects of adenosine on IL-8-
induced neutrophil chemotaxiswere investigated and the involved receptors identiﬁed using adenosine receptor
antagonists. The modulatory effects of ticagrelor on adenosine-mediated changes in neutrophil chemotaxis and
phagocytosis of Streptococcus pneumoniae were determined in the presence of erythrocytes to replicate
physiological conditions of cellular adenosine uptake. Low-concentration adenosine (10−8 M) signiﬁcantly
increased IL-8-induced neutrophil chemotaxis (% neutrophil chemotaxis: adenosine 28.7% ± 4.4 vs. control
22.6%± 2.4; p b 0.01) by acting on the high-afﬁnity A1 receptor. Erythrocytes attenuated the effect of adenosine,
although this was preserved by ticagrelor and dipyridamole (another inhibitor of adenosine uptake) but not by
control or by cangrelor. Similarly, in the presence of erythrocytes, a low concentration of adenosine (10−8M) sig-
niﬁcantly increased neutrophil phagocytic index compared to controlwhen ticagrelorwas present (37.6±6.6 vs.
28.0± 6.6; p= 0.028) but had no effect in the absence of ticagrelor.We therefore conclude that the inhibition of
cellular adenosine reuptake by ticagrelor potentiates the effects of a nanomolar concentration of adenosine on
neutrophil chemotaxis and phagocytosis. This represents a potential mechanism by which ticagrelor could
inﬂuence host defence against bacterial lung infection.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Ticagrelor is a novel class of antiplatelet medication that inhibits
platelet P2Y12 receptors and also inhibits cellular uptake of adenosine
by inhibiting equilibrative nucleoside transporter 1 (ENT1) [1,2]. In
the PLATelet inhibition and patient Outcomes (PLATO) study, ticagrelor
reduced the incidence of adverse cardiovascular events in patients with
acute coronary syndromes (ACS) compared to clopidogrel [3]. Account-
ing for this reduction in cardiovascular events, ticagrelor provides more
potent and consistent P2Y12 inhibition than clopidogrel, leading to a
greater antithrombotic effect [4,5]. In addition, by inhibiting cellular up-
take of adenosine, ticagrelor increases plasma levels of adenosine in ACS44 114 271 1863.
).
. This is an open access article underpatients [6]. Clinically relevant effects of thismechanismhave been sug-
gested by potentiation of the effect of adenosine on coronary blood ﬂow
and dyspnoea by ticagrelor [7,8]. Additional cardiovascular effects of
this mechanism include adenosine-mediated limitation of myocardial
infarct size [9] and adenosine-mediated inhibition of platelet aggrega-
tion by ticagrelor [10].
The reduction in all-cause mortality with ticagrelor compared to
clopidogrel in the PLATO study (HR 0.78; 95% CI 0.69–0.89; p b 0.001)
was unexpected on the basis of previous studies, raising the important
possibility that beneﬁcial non-cardiovascular pleiotropic effects may
have contributed to this mortality reduction. Further analysis of the
PLATO study revealed that ticagrelor was also associated with fewer
pulmonary infections and fewer deaths related to infection and sepsis
than clopidogrel [11–13]. The PLATO study demonstrated that levels
of inﬂammatory markers and neutrophil counts were unexpectedly
slightly, but signiﬁcantly, higher in the ticagrelor group compared to
the clopidogrel group [11]. This further suggests a differential effect of
the two medications on innate immune responses.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cellular levels of adenosine [6], which is known to be a major mediator
of inﬂammation and innate immunity [14]. Adenosine is a degradation
product of ATP that is released during conditions of cellular stress,
such as ischaemia and inﬂammation. At low concentrations, adenosine
signals via A1 andA3 receptors [15]. This primes the innate immune sys-
tem to respond to tissue damage by upregulating pro-inﬂammatory
functions of neutrophils and macrophages, such as chemotaxis (the
directional migration of neutrophils towards chemical stimuli) and
phagocytosis [15]. Conversely, at higher concentrations, adenosine
acts via lower afﬁnity A2A and A2B receptors to limit innate immune
activation to prevent excessive collateral tissue damage [15]. Activation
of A2A and A2B receptors has a wide range of anti-inﬂammatory effects,
including downregulation of phagocytosis, chemotaxis and cytokine
production in neutrophils [15]. Adenosine is rapidly taken up into
erythrocytes by ENT1, resulting in a half-life of less than 10 s in the
blood due to the great number of erythrocytes. ENT1 is almost ubiqui-
tously expressed to a varying degree by human cells and therefore
also regulates extracellular levels of adenosine within tissue [16].
We therefore hypothesised that ticagrelor would potentiate the
effect of adenosine on neutrophil chemotaxis and phagocytosis by
inhibiting cellular uptake of adenosine. Dipyridamole is a known
inhibitor of adenosine uptake [17] and was therefore used as a positive
control.
2. Methods
2.1. Neutrophil and erythrocyte isolation
Neutrophils were isolated from human peripheral blood, based on a
previously described method [18]. Brieﬂy, 8.9 ml venous blood was
collected from healthy volunteers and immediately transferred to
tubes containing 1.1ml of sodium citrate (3.8%;Martindale Pharmaceu-
ticals, UK). The anticoagulated blood was centrifuged at 300 ×g for
20 min to pellet the leukocytes and platelet-rich plasma was discarded.
Erythrocytes were sedimented using 6% dextran (Sigma-Aldrich, UK)
for 30min at room temperature. Leucocyte-richplasmawaswithdrawn,
layered gently over 15 ml Histopaque 1077 (Sigma-Aldrich, UK) and
centrifuged (400 ×g, 25min). Supernatant was discarded and the pellet
subjected to hypotonic lysis (0.2% NaCl) to lyse residual erythrocytes
and then hypertonic rescue buffer (1.6% NaCl supplemented with 0.1%
glucose). The cell suspension was centrifuged (300 ×g, 7 min) and re-
suspended in RPMI buffer (Life Technologies Ltd., UK).
In parallel with the above, 3 ml of blood from the healthy volun-
teers was immediately transferred to tubes containing sodium citrate
3.8%. Platelet-rich plasma was discarded after centrifugation (300 ×g,
20min). The erythrocyte-rich leukocyte pellet was resuspended in buff-
er, layered over 15 ml Histopaque 1077 and centrifuged (400 ×g,
25 min). In order to avoid blocking of the pores of the chemotaxis
assay, the erythrocyte:neutrophil ratio was altered, by increasing the
neutrophil concentration using erythrocyte-free isolated neutrophils,
to give a ﬁnal concentration of 2 × 106 neutrophils ml−1.
2.2. Transmigration of neutrophils in vitro
A 96-well chemotaxis chamber (Neuro Probe, Inc., Gaithersburg,
MD) was used to measure neutrophil chemotaxis, as previously de-
scribed [18]. Brieﬂy, the lower wells of a microplate were loaded with
30 μl of control medium (RPMI) containing different concentrations of
IL-8 (10−10–10−7 M), a potent CXC chemokine that is used to induce
human neutrophil chemotaxis in vitro. To assess the chemotactic re-
sponse of neutrophils to adenosine, 30 μl of adenosine (10−8–10−5 M)
was added to the lower wells. Assays were performed in duplicate.
30 μl of neutrophils (2 × 106 ml−1) ± adenosine ± inhibitors ± eryth-
rocytes was placed directly onto the 5 μm ﬁlter membrane. The chemo-
taxis chamber was incubated for 30 min (37 °C, 5% CO2) as describedpreviously [19]. The number of cells that had migrated into the lower
chamber was calculated as a percentage of the total number of cells
added to the ﬁlter.
2.3. Adenosine and adenosine receptor or reuptake antagonists
Isolated neutrophils were incubated with freshly prepared adeno-
sine (Sigma-Aldrich, UK) at a range of concentrations from 10−11 M to
10−5M immediately prior to studying chemotaxis. Further experiments
were performed following preincubation with adenosine receptor
antagonists (10−7 M) DPCPX (A1 antagonist; Sigma-Aldrich, UK),
SCH58261 (A2A antagonist; Sigma-Aldrich, UK) or MRS 1334 (A3 antag-
onist; Tocris Bioscience, UK) for 20 min (37 °C, 5% CO2).
In some experiments neutrophils, either in the presence or in the
absence of erythrocytes and/or adenosine (10−8 M or 10−5 M), were
incubated with 10−5 or 10−6 M of either cangrelor (gift from The
Medicines Company, New Jersey, USA), ticagrelor (Sequoia Research
Products Limited, UK) or dipyridamole (Sigma-Aldrich, UK) for 20 min
prior to the chemotaxis assay.
2.4. Neutrophil phagocytosis
Neutrophils (2.5 × 106 ml−1), either in the presence or in the
absence of erythrocytes and/or adenosine (10−8 M or 10−5 M), were
resuspended in RPMI with 10% foetal bovine serum with and without
ticagrelor (10−5 M) in a ﬁnal volume of 100 μl in a 96-well plate. Assays
were performed in duplicate. To allow visualisation of neutrophil
phagocytosis bymicroscopy, it was necessary to dilute the erythrocytes,
which were therefore resuspended at 12.5 × 106 ml−1. Heat-killed,
opsonized Streptococcus pneumoniaewas added to achieve a multiplici-
ty of infection (MOI) of 20 and incubated for 30 min (37 °C, 5% CO2).
Cytocentrifuge slides were prepared from the cell suspension using a
Cytospin machine (Shandon, Thermo Scientiﬁc, Waltham, MA) and
stained with modiﬁed Giemsa based stains (Differentiation-Quik,
Reagena, Toivala, Findland). The percentage of neutrophils containing
phagocytosed S. pneumoniae was determined by assessment of 300
neutrophils by light microscopy. Neutrophil phagocytic index was
then determined using the following formula: (total number of
engulfed bacteria / total number of counted neutrophils) × (number
of neutrophils containing engulfed bacteria / total number of counted
neutrophils) [20].
2.5. Statistical methods
Results are presented as mean± SEM. Assuming a mean neutrophil
chemotaxis rate of 20% with SD of 3.0%, 6 repeat experiments were
required to provide 80% power to detect a 25% relative increase in
neutrophil chemotaxis in response to adenosinewithα of 0.05. Statisti-
cal analyses were performed using GraphPad Prism version 6.04
(GraphPad Software Inc., La Jolla, CA). Analysis of variance was used
for statistical signiﬁcance followed by Dunnett's test to compare the
treated groups with vehicle control or Bonferroni's test to compare
selected groups. p value b 0.05 was considered signiﬁcant.
3. Results
3.1. Effect of adenosine on neutrophil chemotaxis
Therewas amaximal response of isolated human neutrophils to IL-8
at a concentration of 10−8 M with lower response at higher concentra-
tion (Fig. 1A), as previously described [18]. A sub-maximal concentra-
tion (10−9 M) was used for all subsequent experiments to investigate
any potential increase or decrease in chemotaxis caused by adenosine.
Next, we investigated whether adenosine acts as a chemoattractant
for neutrophils in vitro. When adenosine (10−8–10−5 M) was added
to the lower wells of the chemotaxis assay chamber, there was no
Fig. 1. Effects of IL-8 and adenosine on neutrophil chemotaxis. Chemotactic response of neutrophils to increasing concentrations of IL-8 (A; n = 4) or adenosine (B; n = 4). The effect of
increasing concentrations of adenosine on neutrophil chemotaxis induced by IL-8 10−9 M (C; n = 8). The number of neutrophils that migrated over 30 min was counted and results
expressed as a percentage of the total number of neutrophils added to the ﬁlter membranes of chemotaxis chambers. Results are presented as mean ± SEM and analysed for statistical
signiﬁcance using one-way analysis of variance followed by Dunnett's t-test. **p b 0.01 and ***p b 0.001 compared to control.
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compared to RPMI control (Fig. 1B). We then tested the effect of the
presence of increasing concentrations of adenosine on the neutrophil
response to IL-8 (10−9M). The presence of adenosine at a concentration
of 10−8 M induced a signiﬁcant increase in neutrophil chemotaxis
(Fig. 1C) and was therefore used in subsequent experiments.
3.2. Identifying the role of adenosine receptors in neutrophil chemotaxis
DPCPX (10−7 M), a speciﬁc antagonist of the A1 receptor [21],
blocked the augmentation of IL-8-induced neutrophil chemotaxis by
adenosine (10−8 M; Fig. 2A) but had no effect in the presence of the
higher concentration of adenosine (10−5 M; Fig. 2B). Conversely, the
treatment of neutrophils with SCH58261 (10−7 M), a speciﬁc antago-
nist of the A2A receptor [22], had no effect in the presence of 10−8 M
adenosine (Fig. 2C) but, in the presence of a higher concentration of
adenosine (10−5 M), signiﬁcantly increased neutrophil chemotaxis to-
wards IL-8 (Fig. 2D). The A3 receptor antagonist MRS 1334 (10−7 M)
did not affect neutrophil chemotaxis in the presence of either 10−8 M
or 10−5 M adenosine (Fig. 2E and F).
3.3. Erythrocytes attenuate the effect of adenosine on neutrophil chemotaxis
To explore the effects of physiological cellular uptake of adenosine,
the effect of adding erythrocytes to the neutrophil suspension was
assessed. Whereas adenosine (10−8 M) signiﬁcantly potentiated
neutrophil chemotaxis towards IL-8 in the absence of erythrocytes,
this effect was not seen in the presence of erythrocytes (Fig. 3).3.4. Ticagrelor and dipyridamole enhance neutrophil chemotaxis by
inhibiting cellular uptake of adenosine
None of the platelet inhibitors tested (cangrelor, ticagrelor and
dipyridamole; 10−5 M) altered IL-8-induced neutrophil chemotaxis in
the presence of erythrocytes and in the absence of adenosine (Fig. 4).
However, in the presence of both erythrocytes and adenosine, ticagrelor
and dipyridamole signiﬁcantly increased IL-8-induced neutrophil
chemotaxis (Fig. 4). No such effect was seen with cangrelor, a P2Y12
inhibitor that has no effect on cellular adenosine uptake [2].
3.5. Ticagrelor potentiates neutrophil phagocytosis induced by low
concentrations of adenosine
In the presence of erythrocytes, a low concentration of adenosine
(10−8 M) signiﬁcantly increased the percentage of neutrophils contain-
ing phagocytosed S. pneumoniae (35.0% ± 1.9 vs. 27.7% ± 2.5; p =
0.0029) (Fig. 5A) and neutrophil phagocytic index compared to control
(37.6 ± 6.6 vs. 28.0 ± 6.6; p = 0.028) (Fig. 5B) when ticagrelor
(10−5 M)was present. In contrast, in the absence of ticagrelor, low con-
centration adenosine (10−8) had no effect on percentage of neutrophils
containing phagocytosed S. pneumoniae (27.7% ± 2.5 vs. 27.4% ± 3.2;
p N 0.05) (Fig. 5A) or phagocytic index (25.3 ± 5.6 vs. 25.1 ± 7.5;
p N 0.05) (Fig. 5B). A higher concentration of adenosine (10−5 M)
did not affect neutrophil phagocytosis, likely due to the activation of
lower-afﬁnity A2A receptors.
The potentiation of adenosine-mediated neutrophil phagocytosis
caused by ticagrelorwas A1 receptor dependent (Fig. 6). In the presence
of erythrocytes, DPCPX (an A1 receptor antagonist) signiﬁcantly
Fig. 2. Effect of adenosine receptor antagonists on neutrophil chemotaxis in the presence of adenosine. The effect of the A1 antagonist DPCPX 10−7 M (A and B), the A2 antagonist
SCH58261 10−7 M (C and D) and the A3 antagonist MRS 1334 10−7 M (E and F) on neutrophil migration to IL-8 10−9 M over 30 min in the presence or absence of adenosine 10−8 M
(A, C and E; n=6) or adenosine 10−5M (B, D and F; n=7). All inhibitorswere assessedwithin the same experiment but are divided into different panels for clarity. Results are presented
as mean ± SEM and analysed for statistical signiﬁcance using one-way analysis of variance followed by Bonferroni's test for multiple comparisons. *p b 0.05 and **p b 0.01.
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of low-concentration adenosine (10−8 M) on the percentage of neutro-
phils containing phagocytosed bacteria (p b 0.01) (Fig. 6A) and the
neutrophil phagocytic index (p b 0.01) (Fig. 6B).
4. Discussion
We have shown for the ﬁrst time that adenosine reuptake inhibition
with ticagrelor potentiates the increases in neutrophil chemotaxis andFig. 3. Effect of erythrocytes on the response to adenosine. Chemotactic response of
neutrophils to IL-8 10−9 M, in the presence of adenosine 10−8 M and in the absence
(white columns) or presence (black columns) of erythrocytes (n = 14). Results are
presented as mean ± SEM and analysed for statistical signiﬁcance using one-way analysis
of variance followed by Bonferroni's test formultiple comparisons. **p b 0.01 and *** b0.001.phagocytosis mediated by adenosine in vitro. It has now been consis-
tently demonstrated that ticagrelor inhibits cellular uptake of adenosine
[1,2] and we have also conﬁrmed this in our laboratory (data not
shown). This has been shown to increase plasma levels of adenosine
in patients with ACS [6] and so supports the hypothesis that ticagrelor
treatment might have relevant effects on neutrophil function in vivo.
Four different adenosine receptors exist, which are activated at different
concentrations of adenosine and expressed on a wide range of different
cell types [23]. The resultant pleiotropic effects of this mechanism are
therefore complex. This study demonstrates that thismechanismaffects
important neutrophil responses, in addition to previously described
cardiovascular effects [7–10]. Comparison with dipyridamole suggests
that this is a class-effect of ENT1 inhibitors.
To investigate whether adenosine reuptake inhibition by ticagrelor
might inﬂuence leukocyte function, we ﬁrst identiﬁed the appropriate
concentration of IL-8 to induce neutrophil chemotaxis. We found that
IL-8 was able to induce signiﬁcant chemotaxis with a maximum effect
at a concentration of 10−8 M, consistent with previous studies [18,24].
Although adenosine itself was not able to act as a chemoattractant for
neutrophils, a nanomolar concentration of adenosine was found to
potentiate IL-8-induced neutrophil chemotaxis with loss of this effect
at micromolar concentrations. This supports previous work suggesting
that the lower concentrations of adenosine promote neutrophil chemo-
taxis, whereas high concentrations of adenosine inhibit neutrophil
chemotaxis [25]. A similar resultwas also observed by adding adenosine
(10−9M to 10−6 M) in the lowerwells with fMLP in a chemotaxis assay
[26]. In addition, adenosine had a similar effect on human monocytes
[27]. Analogous ﬁndings have been reported also for ATP, from which
adenosine is derived by intracellular and extracellular breakdown [26,
28].
To explore the function of different adenosine receptors in neutro-
phil chemotaxis, speciﬁc adenosine receptor antagonists were used in
Fig. 4. Effects of cangrelor, ticagrelor and dipyridamole on neutrophil chemotaxis in the presence of erythrocytes and the absence or the presence of adenosine. Chemotactic response of
neutrophils to IL-8 10−9 M, in the presence of erythrocytes and without (white columns) or with (black columns) addition of adenosine 10−8 M, showing the effects of cangrelor,
ticagrelor and dipyridamole all at concentrations of either (A) 10−5Mor (B) 10−6M, compared to vehicle control (n=7). Results are presented asmean±SEMand analysed for statistical
signiﬁcance using one-way analysis of variance followed by Bonferroni's test for multiple comparisons.*p b 0.05, ***p b 0.001 and **** b0.0001.
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revealed that the low concentration of adenosine stimulates neutrophil
chemotaxis through the A1 receptor. In contrast, activation of the A2A
receptor by a high concentration of adenosine attenuates neutrophil
chemotaxis in response to IL-8. Our ﬁndings are consistent with previ-
ous studies indicating that the high afﬁnity A1 receptor promotes
neutrophil chemotaxis, whereas the lower afﬁnity A2A receptor limits
neutrophil chemotaxis [25,27,29]. This likely reﬂects the different
signalling pathways linked to these receptors: A1 is Gi/o-coupled and
the occupancy of A1 diminishes cAMP accumulation, whereas A2A is
Gs-coupled and the binding of adenosine to the A2A receptor increases
the formation of cAMP [29]. The role of A3 receptors in neutrophil
chemotaxis is more controversial. Some studies showed that A3 recep-
tors enhance neutrophil chemotaxis [26,30], whereas other studies,
like our own, have not conﬁrmed this [31,32]. Our ﬁndings are also
consistent with previous studies that show that nanomolar concentra-
tions of adenosine stimulate neutrophil phagocytosis by acting onhigh-afﬁnity A1 receptors [33,34]. Previous studies have demonstrated
an inhibitory effect of micromolar concentrations of adenosine on
neutrophil phagocytosis mediated by A2A receptors [33,34], although
our results demonstrate a more neutral effect.
Although no study has focused on the effect of ticagrelor as an
adenosine uptake inhibitor on neutrophil function, dipyridamole has
been found to exert beneﬁcial pleiotropic effects secondary to an action
on neutrophils. For example, preoperative treatmentwith dipyridamole
for patients who undergo coronary artery bypass graft inhibited neutro-
phil superoxide anion generation and neutrophil adhesion to endothe-
lial cells [35]. These researchers proposed that this mechanism is
mediated by increased adenosine levels. Another study suggested
that dipyridamole enhanced the inhibitory effects of adenosine, which,
in turn, reduced the effect of fMLP-activated neutrophil hydrogen
peroxide (H2O2) production [27].
Our results demonstrate how adenosine uptake inhibition by
dipyridamole and ticagrelor can preserve the extracellular concentration
Fig. 5. Effect of ticagrelor on changes in neutrophil phagocytosis induced by low and high concentrations of adenosine in the presence of erythrocytes. Effect of ticagrelor (10−5 M) on
changes in neutrophil phagocytosis of S. pneumoniae, determined by percentage of neutrophils containing phagocytosed S. pneumoniae (A) and phagocytic index (B), induced by
10−8 M and 10−5 M adenosine in the presence of erythrocytes (n = 8). Results are expressed as mean ± SEM and analysed for statistical signiﬁcance using two-way ANOVA followed
by Bonferroni's test for multiple comparisons. *p b 0.05, **p b 0.01.
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neutrophil chemotaxis and phagocytosis through stimulation of A1 re-
ceptors. Although ticagrelor has been shown to induce ATP release
from human erythrocytes in vitro, which is subsequently degraded to
adenosine [36], our results did not demonstrate any effect via this
mechanism on neutrophil recruitment, since there was no effect when
ticagrelor was combined with erythrocytes and neutrophils in the
absence of added adenosine.
P2Y12 inhibitors reduce platelet-neutrophil aggregate formation and
release of inﬂammatory-mediators from platelet α-granules [37].
Platelet–leukocyte aggregates are pro-inﬂammatory and may be harm-
ful in conditions associated with excessive immune activation, such as
sepsis and acute lung injury [38]. However, platelet–neutrophil aggre-
gates are primed for phagocytosis and intracellular killing [38] and it
is therefore feasible that inhibiting their formation may hinder initial
resolution of bacterial infection. It is possible that this is to some extent
counter-balanced by ticagrelor potentiating A1-mediated neutrophil
chemotaxis and phagocytosis at low levels of adenosine, such as may
occur at the early stages of infection, however. In conditions such as
sepsis, adenosine is present at higher concentrations and acts on A2A
and A2B receptors to dampen excessive inﬂammation [39]. Therefore,
in contrast, potentiating the effect of adenosine in sepsis might have
anti-inﬂammatory effects. Taken together, theseﬁndings providemech-
anisms that may be relevant to the observation of fewer pulmonaryFig. 6. Interaction between ticagrelor and the A1 receptor antagonist DPCPX. Effect of ticagrelor (
percentage of neutrophils containing phagocytosed S. pneumoniae (A) and phagocytic index
expressed as mean ± SEM and analysed for statistical signiﬁcance using two-way ANOVA folloinfections and fewer deaths following pulmonary infections and sepsis
during treatment with ticagrelor compared to clopidogrel in the
PLATO study.
In conclusion, ticagrelor enhanced the stimulatory effect of a
nanomolar concentration of adenosine on neutrophil chemotaxis and
phagocytosis under physiological conditions of cellular adenosine
uptake. Ticagrelor and dipyridamole had no direct effect on neutrophil
recruitment and phagocytosis but were able to preserve the enhancing
effect of adenosine in the presence of erythrocytes through the inhibi-
tion of adenosine reuptake. Further work is required to determine
whether adenosine might mediate immunostimulatory effects of
ticagrelor that could provide protection against pulmonary infection
andwhether there is an optimal level of ENT1 inhibition thatmaximises
any such effects.
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